OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	376
Bimekizumab effective across the axSpA spectrum	319
Genome-wide mutagenesis reported in systemic sclerosis	303
The role of the patient in rheumatology	234
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	228
Rheumatic diseases on the rise	194
A role for TGFβ and EBV in MIS-C pathogenesis	191
Obexelimab reduces the risk of IgG4-RD flare	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	179
Osteoarthritis as a systemic disease	170
Towards better management of sterile bone inflammation	167
New drug formulation reduces bone loss	159
The value of comparative efficacy studies in informing rheumatology guidelines	158
The 2022 ACR vaccination guideline: a call-to-action	155
Appraising the evolving landscape of protease inhibition in osteoarthritis	154
MIS-C: myths have been debunked, but mysteries remain	151
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	141
FOXP3 splice variant is associated with autoimmune disease	137
Urchin-like nanoparticles for miRNA therapy of OA	136
Inflammation across tissues: can shared cell biology help design smarter trials?	132
Down syndrome: insights into autoimmune mechanisms	130
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	130
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	128
Co-trimoxazole reduces mortality in anti-MDA5-DM	125

Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	124
Rheumatic diseases and metabolism: where centre and periphery meet	116
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	115
Wnt-induced IGF1 drives OA	115
A direct link between SARS-CoV-2 and bone loss	114
Calprotectin tracks tocilizumab-treated RA	110
Fumarate drives interferon release in systemic sclerosis monocytes	105
S100A4 inhibition targets fibrosis in SSc	104
Low back pain is a growing concern	99
Fibroblast TGFβ drives treatment-refractory RA	96
Author Correction: Proposals for the rheumatological use of JAK inhibitors	94
COPA syndrome spans multiple organs but is defined by STING in the lung	94
Pain in systemic lupus erythematosus: emerging insights and paradigms	93
Guiding ILD management in systemic autoimmune rheumatic diseases	92
Immune reset and immune retune: approaching cure?	92
Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome	86
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	81
Rheumatology in the digital health era: status quo and quo vadis?	79
Targeting the IVD clock to halt degeneration	78
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Which DMARD for ICI-associated arthritis?	78
Phase III trial of telitacicept in SLE	75
A path towards personalized medicine for autoinflammatory and related diseases	73
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	71
Cell-free DNA fragmentation signatures link cancer and autoimmunity	71
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	69
Erosive cargo from synovial fibroblasts	69
ERAP1 and the return of the UPR in ankylosing spondylitis	68
CAR T cells induce drug-free SLE remission	63
Targeting ferroptosis resistance in RA fibroblast-like synoviocytes	62
Insights into IVDD pathogenesis in 2024	62
Macrophage-coated nanocarriers for gouty arthritis	60
Blocking CDK7 attenuates inflammatory arthritis	57
RA risk from occupational inhalation	57
Repolarizing macrophages using antagomirs	57
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	57